Financial Contrast: PAVmed (PAVM) versus Its Rivals

PAVmed (NASDAQ:PAVM) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare PAVmed to similar businesses based on the strength of its valuation, profitability, institutional ownership, risk, earnings, analyst recommendations and dividends.

Profitability

This table compares PAVmed and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PAVmed	-10,794.64%	-126.43%	-25.49%
PAVmed Competitors	-304.20%	-315.07%	-22.11%

Analyst Recommendations

This is a breakdown of current ratings for PAVmed and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1	1	1	0	2.00
PAVmed Competitors	4291	10579	18364	831	2.46

PAVmed presently has a consensus price target of $56.00, indicating a potential upside of 3,683.78%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.44%. Given PAVmed’s higher possible upside, equities research analysts clearly believe PAVmed is more favorable than its rivals.

Valuation & Earnings

This table compares PAVmed and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
PAVmed	$70,000.00	$400,000.00	-0.09
PAVmed Competitors	$1.90 billion	$135.83 million	5.85

PAVmed’s rivals have higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 13.4% of PAVmed shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

PAVmed has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, PAVmed’s rivals have a beta of 2.57, suggesting that their average share price is 157% more volatile than the S&P 500.

Summary

PAVmed rivals beat PAVmed on 11 of the 13 factors compared.

PAVmed Company Profile

PAVmed Inc. is a diversified medical technology company that develops and commercializes diagnostic and therapeutic products intended to address significant unmet needs in healthcare. Its portfolio has included medical devices, diagnostic technologies and digital health solutions, with a focus on products designed to improve disease detection, treatment and patient care. One of PAVmed’s principal areas of activity has been its relationship with Lucid Diagnostics, a subsidiary focused on early detection of esophageal disease.